Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is one of the 15 stocks set to explode in 2026.

Morgan Stanley Reaffirms “Buy” Rating on Ultragenyx Pharmaceutical (RARE) with $55 PT

On November 5, 2025, analyst Maxwell Skor from Morgan Stanley reaffirmed his “Buy” rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) with a $55 price target.

The analyst’s bullish stance stemmed from Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) strong financial position, alongside its pivotal late-stage pipeline. Having secured $400 million in non-dilutive financing from OMERS recently, the company strengthened its liquidity to advance multiple product launches while deferring payments until 2028.

Skor believes this financing will critically support Ultragenyx Pharmaceutical Inc.’s (NASDAQ:RARE) goal to become profitable by 2027. Furthermore, the analyst highlighted the significance of the upcoming Phase 4 Orbit and Cosmic trials for Setrusumab. The antibody is a potential breakthrough therapy for Osteogenesis Imperfecta, which is expected to deliver significant reductions in fractures and improvements in patient outcomes.

On the previous day, Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) announced the expansion of its 2022 partnership with OMERS. With this expansion, the company made a royalty sale, granting OMERS an additional 25% royalty interest in Crysvita sales in the U.S. and Canada. This reinforced investor confidence in the company’s rare-disease portfolio and provided strategic capital to fund its growth trajectory.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company, develops and commercializes innovative therapies. These therapies target patients suffering from serious and ultra-rare genetic diseases with no or limited existing treatment options.

While we acknowledge the potential of RARE to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than RARE and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 7 Best Oil and Gas Penny Stocks to Buy According to Analysts and Billionaire Jacob Rothschild’s RIT Capital Partners: 9 Stocks with Huge Upside Potential.

Disclosure: None.